ABSTRACT Background and Aims Withdrawal of immunomodulators (IMMs) or tumor
necrosis factor (TNF) antagonists in patients with inflammatory bowel diseases (IBD) in …

There are now a growing number of licensed biological therapies for patients with Crohn's
disease. However, there can be significant costs associated with long-term maintenance …

Background Whether infliximab therapy can be successfully discontinued after patients with
Crohn's disease have attained sustained, clinical, biochemical, and endoscopic remission is …

Background Owing to growing number of therapeutic options with similar efficacy and safety,
we compared the acceptability of therapeutic maintenance regimens in inflammatory bowel …

Background Inflammatory bowel disease (IBD) is often managed with anti‐tumour necrosis
factor‐α therapy (anti‐TNFα), but treatment efficacy is compromised by high annual rates of …

Background Despite its effectiveness in treating Crohn's disease, adalimumab is associated
with an increased risk of infections and high health-care costs. We aimed to assess clinical …

Monocytes are involved in the upstream inflammatory process in the immune reaction in
inflammatory bowel disease (IBD). Patients with IBD who discontinued biologics have been …

Background & Aims Discontinuation of anti–tumor necrosis factor-α treatment (anti-
TNF)(infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is …

Introduction Biologic therapy is an effective treatment for inflammatory bowel disease [IBD].
However due to cost and safety concerns, dose de-escalation strategies after achieving …

Background The risk of relapse after anti-tumour necrosis factor [TNF] therapy
discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed …